The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives In a time of uncertainty, “react to the knowns, not the fear” - The Cancer Letter

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives In a time of uncertainty, “react to the knowns, not the fear” - The Cancer Letter

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing: “Changing the paradigm of how research is funded and how care is funded, I think makes us all a bit nervous,” said Lynch, president and director of Fred Hutch Can…